
Francis Berenbaum

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1558274/publications.pdf Version: 2024-02-01



FDANCIS REDENBALIM

#	Article	IF	CITATIONS
1	OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis and Cartilage, 2014, 22, 363-388.	1.3	2,298
2	Osteoarthritis: an update with relevance for clinical practice. Lancet, The, 2011, 377, 2115-2126.	13.7	1,705
3	Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis and Cartilage, 2013, 21, 16-21.	1.3	1,197
4	The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nature Reviews Rheumatology, 2010, 6, 625-635.	8.0	1,029
5	Primary culture and phenotyping of murine chondrocytes. Nature Protocols, 2008, 3, 1253-1260.	12.0	567
6	Tendon injury: from biology to tendon repair. Nature Reviews Rheumatology, 2015, 11, 223-233.	8.0	335
7	Osteoarthritis year in review 2019: epidemiology and therapy. Osteoarthritis and Cartilage, 2020, 28, 242-248.	1.3	334
8	Obesity and osteoarthritis: more complex than predicted!. Annals of the Rheumatic Diseases, 2006, 65, 1403-1405.	0.9	281
9	Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Annals of the Rheumatic Diseases, 2019, 78, 209-217.	0.9	273
10	Diabetes Is an Independent Predictor for Severe Osteoarthritis. Diabetes Care, 2013, 36, 403-409.	8.6	270
11	Stigmasterol: a phytosterol with potential anti-osteoarthritic properties. Osteoarthritis and Cartilage, 2010, 18, 106-116.	1.3	269
12	Homeostatic Mechanisms in Articular Cartilage and Role of Inflammation in Osteoarthritis. Current Rheumatology Reports, 2013, 15, 375.	4.7	259
13	Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis. RMD Open, 2015, 1, e000077-e000077.	3.8	235
14	The Regulation of Chondrocyte Function by Proinflammatory Mediators. Clinical Orthopaedics and Related Research, 2004, 427, S37-S46.	1.5	222
15	Is osteoarthritis a metabolic disease?. Joint Bone Spine, 2013, 80, 568-573.	1.6	220
16	Osteoarthritis, inflammation and obesity. Current Opinion in Rheumatology, 2013, 25, 114-118.	4.3	212
17	Anti-tumor necrosis factor ? therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: A followup report of tolerability and efficacy. Arthritis and Rheumatism, 2003, 48, 2019-2024.	6.7	204
18	The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine, 2011, 78, 598-603.	1.6	204

#	Article	IF	CITATIONS
19	Transcription factor EGR1 directs tendon differentiation and promotes tendon repair. Journal of Clinical Investigation, 2013, 123, 3564-3576.	8.2	201
20	Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Annals of the Rheumatic Diseases, 2016, 75, 37-44.	0.9	194
21	Crucial role of visfatin/pre–B cell colonyâ€enhancing factor in matrix degradation and prostaglandin E ₂ synthesis in chondrocytes: Possible influence on osteoarthritis. Arthritis and Rheumatism, 2008, 58, 1399-1409.	6.7	179
22	A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. Annals of Internal Medicine, 2020, 172, 819-821.	3.9	177
23	Metabolic syndrome-associated osteoarthritis. Current Opinion in Rheumatology, 2017, 29, 214-222.	4.3	168
24	Review: Metabolic Regulation of Inflammation in Osteoarthritis. Arthritis and Rheumatology, 2017, 69, 9-21.	5.6	164
25	The Role of ILâ€l and ILâ€l Ra in Joint Inflammation and Cartilage Degradation. Vitamins and Hormones, 2006, 74, 371-403.	1.7	161
26	The ESPOIR cohort: A ten-year follow-up of early arthritis in France. Joint Bone Spine, 2007, 74, 440-445.	1.6	161
27	Metabolic stress-induced joint inflammation and osteoarthritis. Osteoarthritis and Cartilage, 2015, 23, 1955-1965.	1.3	160
28	Modern-day environmental factors in the pathogenesis of osteoarthritis. Nature Reviews Rheumatology, 2018, 14, 674-681.	8.0	159
29	Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype. Annals of the Rheumatic Diseases, 2011, 70, 1354-1356.	0.9	146
30	Emerging targets in osteoarthritis therapy. Current Opinion in Pharmacology, 2015, 22, 51-63.	3.5	142
31	A Phase <scp>II</scp> Trial of Lutikizumab, an Anti–Interleukinâ€1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis and Rheumatology, 2019, 71, 1056-1069.	5.6	137
32	Fatigue in chronic inflammation - a link to pain pathways. Arthritis Research and Therapy, 2015, 17, 254.	3.5	135
33	Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). Annals of the Rheumatic Diseases, 2015, 74, 1725-1733.	0.9	130
34	Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage: Critical roles of the ERK-1/2 and p38 signaling pathways. Arthritis and Rheumatism, 2004, 50, 2829-2838.	6.7	124
35	Mechanical loading highly increases IL-6 production and decreases OPG expression by osteoblasts. Osteoarthritis and Cartilage, 2009, 17, 473-481.	1.3	123
36	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open, 2021, 7, e001814.	3.8	121

#	Article	IF	CITATIONS
37	Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain. Journal of Bone and Joint Surgery - Series A, 2018, 100, 666-677.	3.0	120
38	Signaling transduction: target in osteoarthritis. Current Opinion in Rheumatology, 2004, 16, 616-622.	4.3	119
39	Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Annals of the Rheumatic Diseases, 2019, 78, 413-420.	0.9	115
40	Immortalized human adult articular chondrocytes maintain cartilage-specific phenotype and responses to interleukin-11². Arthritis and Rheumatism, 2000, 43, 2189-2201.	6.7	114
41	A randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis. Annals of the Rheumatic Diseases, 2012, 71, 1454-1460.	0.9	111
42	The danger from within: alarmins in arthritis. Nature Reviews Rheumatology, 2016, 12, 669-683.	8.0	111
43	Mesenchymal Stem Cell Therapy Regenerates the Native Bone-Tendon Junction after Surgical Repair in a Degenerative Rat Model. PLoS ONE, 2010, 5, e12248.	2.5	111
44	Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Research and Therapy, 2006, 8, R114.	3.5	106
45	Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology, 2009, 48, 1429-1434.	1.9	106
46	Critical role of C/EBPÎ [^] and C/EBPÎ ² factors in the stimulation of the cyclooxygenase-2 gene transcription by interleukin-1Î ² in articular chondrocytes. FEBS Journal, 2000, 267, 6798-6809.	0.2	105
47	Induction of an Inflammatory and Prodegradative Phenotype in Autologous Fibroblastâ€like Synoviocytes by the Infrapatellar Fat Pad From Patients With Knee Osteoarthritis. Arthritis and Rheumatology, 2014, 66, 2165-2174.	5.6	104
48	Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Ageing Research Reviews, 2019, 55, 100946.	10.9	103
49	Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Annals of the Rheumatic Diseases, 2020, 79, 800-810.	0.9	98
50	Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes: possible involvement in osteoarthritis pain. Arthritis Research and Therapy, 2014, 16, R16.	3.5	96
51	Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology, 2012, 51, 60-68.	1.9	95
52	Interleukin-1-Induced Prostaglandin E2 Biosynthesis in Human Synovial Cells Involves the Activation of Cytosolic Phospholipase A2 and Cyclooxygenase-2. FEBS Journal, 1994, 226, 125-131.	0.2	94
53	Assessing health-related quality of life in hand osteoarthritis: a literature review. Annals of the Rheumatic Diseases, 2011, 70, 921-928.	0.9	93
54	Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort. Joint Bone Spine, 2015, 82, 345-351.	1.6	92

#	Article	IF	CITATIONS
55	Characterization of diabetic osteoarthritic cartilage and role of high glucose environment on chondrocyte activation: toward pathophysiological delineation of diabetes mellitus-related osteoarthritis. Osteoarthritis and Cartilage, 2015, 23, 1513-1522.	1.3	91
56	Osteoarthritis and obesity: Experimental models. Joint Bone Spine, 2008, 75, 675-679.	1.6	89
57	Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis. Arthritis Research and Therapy, 2014, 16, R38.	3.5	88
58	Commentary on recent therapeutic guidelines for osteoarthritis. Seminars in Arthritis and Rheumatism, 2015, 44, 611-617.	3.4	88
59	Cartilage breakdown in rheumatoid arthritis. Joint Bone Spine, 2006, 73, 29-36.	1.6	87
60	Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Annals of the Rheumatic Diseases, 2015, 74, 843-850.	0.9	86
61	The Phenotypic Approach to Osteoarthritis: A Look at Metabolic Syndrome-Associated Osteoarthritis. Joint Bone Spine, 2019, 86, 725-730.	1.6	83
62	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis. Drugs and Aging, 2015, 32, 179-187.	2.7	82
63	Prostaglandin E2 synthesis in cartilage explants under compression: mPGES-1 is a mechanosensitive gene. Arthritis Research and Therapy, 2006, 8, R135.	3.5	81
64	Gastrointestinal and Cardiovascular Risks of Nonsteroidal Anti-inflammatory Drugs. American Journal of Medicine, 2008, 121, 464-474.	1.5	81
65	Concomitant Recruitment of ERK1/2 and p38 MAPK Signalling Pathway Is Required for Activation of Cytoplasmic Phospholipase A2via ATP in Articular Chondrocytes. Journal of Biological Chemistry, 2003, 278, 13680-13687.	3.4	80
66	Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Annals of the Rheumatic Diseases, 2007, 66, 1610-1615.	0.9	80
67	Differential expression of interleukin-17 and interleukin-22 in inflamed and non-inflamed synovium from osteoarthritis patients. Osteoarthritis and Cartilage, 2015, 23, 1843-1852.	1.3	80
68	Knee and hip intra-articular adipose tissues (IAATs) compared with autologous subcutaneous adipose tissue: a specific phenotype for a central player in osteoarthritis. Annals of the Rheumatic Diseases, 2017, 76, 1142-1148.	0.9	78
69	Synergistic Effect of Interleukin- 1^2 and Tumor Necrosis Factor $1\pm$ on PGE2Production by Articular Chondrocytes Does Not Involve PLA2Stimulation. Experimental Cell Research, 1996, 222, 379-384.	2.6	75
70	How to define responders in osteoarthritis. Current Medical Research and Opinion, 2013, 29, 719-729.	1.9	75
71	Does platelet-rich plasma have a role in the treatment of osteoarthritis?. Joint Bone Spine, 2016, 83, 31-36.	1.6	74
72	EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. RMD Open, 2019, 5, e001014.	3.8	73

#	Article	IF	CITATIONS
73	The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Annals of the Rheumatic Diseases, 2011, 70, 818-822.	0.9	72
74	Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Annals of the Rheumatic Diseases, 2004, 63, 1419-1426.	0.9	71
75	Culture and Phenotyping of Chondrocytes in Primary Culture. , 2004, 100, 001-014.		70
76	Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Joint Bone Spine, 2007, 74, 197-200.	1.6	70
77	Mobile Health Apps for Self-Management of Rheumatic and Musculoskeletal Diseases: Systematic Literature Review. JMIR MHealth and UHealth, 2019, 7, e14730.	3.7	70
78	Immature murine articular chondrocytes in primary culture: a new tool for investigating cartilage. Osteoarthritis and Cartilage, 2005, 13, 243-249.	1.3	69
79	Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy. Acta Neuropathologica Communications, 2014, 2, 154.	5.2	68
80	Signal transduction pathways: new targets for treating rheumatoid arthritis. Joint Bone Spine, 2004, 71, 503-510.	1.6	67
81	Differentiation regulates interleukin-1β-induced cyclo-oxygenase-2 in human articular chondrocytes: role of p38 mitogen-activated protein kinase. Biochemical Journal, 2002, 362, 367-373.	3.7	65
82	Alternative and complementary therapies in osteoarthritis and cartilage repair. Aging Clinical and Experimental Research, 2020, 32, 547-560.	2.9	65
83	Osteoarthritis and inflammation: a serious disease with overlapping phenotypic patterns. Postgraduate Medicine, 2020, 132, 377-384.	2.0	65
84	Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Research and Therapy, 2013, 15, R210.	3.5	64
85	Brief Report: A Phase <scp>II</scp> b Trial of a Novel Extendedâ€Release Microsphere Formulation of Triamcinolone Acetonide for Intraarticular Injection in Knee Osteoarthritis. Arthritis and Rheumatology, 2018, 70, 204-211.	5.6	62
86	Muscle involvement in sarcoidosis: a retrospective and followup studies. Journal of Rheumatology, 2006, 33, 98-103.	2.0	62
87	New horizons and perspectives in the treatment of osteoarthritis. Arthritis Research and Therapy, 2008, 10, S1.	3.5	61
88	Stressâ€induced cartilage degradation does not depend on the NLRP3 inflammasome in human osteoarthritis and mouse models. Arthritis and Rheumatism, 2012, 64, 3972-3981.	6.7	59
89	Induction of the chemokine IL-8/Kc by the articular cartilage: Possible influence on osteoarthritis. Joint Bone Spine, 2012, 79, 604-609.	1.6	58
90	Epidural Lipomatosis. Spine, 1994, 19, 251-254.	2.0	57

#	Article	IF	CITATIONS
91	Stress-induced signaling pathways in hyalin chondrocytes: inhibition by Avocado–Soybean Unsaponifiables (ASU). Osteoarthritis and Cartilage, 2008, 16, 373-384.	1.3	57
92	Association between osteoarthritis and dyslipidaemia: a systematic literature review and meta-analysis. RMD Open, 2017, 3, e000442.	3.8	57
93	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert Review of Clinical Immunology, 2020, 16, 659-666.	3.0	57
94	Transcriptional regulation of inflammatory secreted phospholipases A2. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2000, 1488, 149-158.	2.4	56
95	Differentiation regulates interleukin-1β-induced cyclo-oxygenase-2 in human articular chondrocytes: role of p38 mitogen-activated protein kinase. Biochemical Journal, 2002, 362, 367.	3.7	56
96	Proinflammatory Actions of Visfatin/Nicotinamide Phosphoribosyltransferase (Nampt) Involve Regulation of Insulin Signaling Pathway and Nampt Enzymatic Activity. Journal of Biological Chemistry, 2012, 287, 15100-15108.	3.4	56
97	Cartilage-gut-microbiome axis: a new paradigm for novel therapeutic opportunities in osteoarthritis. RMD Open, 2019, 5, e001037.	3.8	56
98	EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2020, 79, 69-76.	0.9	55
99	Identification of Soluble 14â€3â€3â^Š as a Novel Subchondral Bone Mediator Involved in Cartilage Degradation in Osteoarthritis. Arthritis and Rheumatism, 2013, 65, 1831-1842.	6.7	54
100	2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2022, 81, 1065-1071.	0.9	54
101	The brain–joint axis in osteoarthritis: nerves, circadian clocks and beyond. Nature Reviews Rheumatology, 2016, 12, 508-516.	8.0	53
102	Induction of Secreted Type IIA Phospholipase A2 Gene Transcription by Interleukin-1β. Journal of Biological Chemistry, 2000, 275, 22686-22694.	3.4	52
103	Antirheumatic Disease Therapies for the Treatment of COVIDâ€19: A Systematic Review and Metaâ€Analysis. Arthritis and Rheumatology, 2021, 73, 36-47.	5.6	52
104	A potential role of chondroitin sulfate on bone in osteoarthritis: inhibition of prostaglandin E2 and matrix metalloproteinases synthesis in interleukin-1β- stimulated osteoblasts. Osteoarthritis and Cartilage, 2012, 20, 127-135.	1.3	51
105	Osteoarthritis endotype discovery via clustering of biochemical marker data. Annals of the Rheumatic Diseases, 2022, 81, 666-675.	0.9	51
106	Proinflammatory cytokines, prostaglandins, and the chondrocyte: mechanisms of intracellular activation. Joint Bone Spine, 2000, 67, 561-564.	1.6	50
107	Rituximab Treatment for Spondyloarthritis. A Nationwide Series: Data from the AIR Registry of the French Society of Rheumatology. Journal of Rheumatology, 2012, 39, 2327-2331.	2.0	50
108	Priorities for the effective implementation of osteoarthritis management programs: an OARSI international consensus exercise. Osteoarthritis and Cartilage, 2019, 27, 1270-1279.	1.3	49

#	Article	IF	CITATIONS
109	Association between osteoarthritis and increased risk of dementia. Medicine (United States), 2019, 98, e14355.	1.0	49
110	Role of C-type natriuretic peptide signalling in maintaining cartilage and bone function. Osteoarthritis and Cartilage, 2014, 22, 1800-1807.	1.3	48
111	Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment?. Scandinavian Journal of Rheumatology, 2016, 45, 87-98.	1.1	48
112	Social media use among young rheumatologists and basic scientists: results of an international survey by the Emerging EULAR Network (EMEUNET). Annals of the Rheumatic Diseases, 2017, 76, 712-715.	0.9	48
113	Bone mineral density and joint cartilage: four clinical settings of a complex relationship in osteoarthritis. Annals of the Rheumatic Diseases, 2011, 70, 1523-1525.	0.9	47
114	Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement. Osteoarthritis and Cartilage, 2015, 23, 2086-2093.	1.3	47
115	Involvement of central microsomal prostaglandin E synthase-1 in IL-1Î ² -induced anorexia. Physiological Genomics, 2006, 25, 485-492.	2.3	46
116	Comparison of Certolizumab Pegol with Other Anticytokine Agents for Treatment of Rheumatoid Arthritis: A Multiple-treatment Bayesian Metaanalysis. Journal of Rheumatology, 2011, 38, 835-845.	2.0	45
117	Recommendations of the French Society of Rheumatology on pharmacological treatment of knee osteoarthritis. Joint Bone Spine, 2020, 87, 548-555.	1.6	45
118	Human chondrocyte culture models for studying cyclooxygenase expression and prostaglandin regulation of collagen gene expression. Osteoarthritis and Cartilage, 1999, 7, 386-388.	1.3	44
119	Osteoarthritis year 2010 in review: pharmacological therapies. Osteoarthritis and Cartilage, 2011, 19, 361-365.	1.3	43
120	Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype. Postgraduate Medical Journal, 2012, 88, 240-242.	1.8	43
121	Kinetic Profiles and Management of Hepatitis B Virus Reactivation in Patients With Immuneâ€Mediated Inflammatory Diseases. Arthritis Care and Research, 2013, 65, 1504-1514.	3.4	43
122	Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review. PLoS ONE, 2015, 10, e0145076.	2.5	42
123	EULAR recommendations for intra-articular therapies. Annals of the Rheumatic Diseases, 2021, 80, 1299-1305.	0.9	42
124	Posttranscriptional effect of insulin-like growth factor-I on interleukin-1beta-induced type II-secreted phospholipase A2 gene expression in rabbit articular chondrocytes Journal of Clinical Investigation, 1997, 99, 1864-1872.	8.2	42
125	"Let's Talk about OA Pain†A Qualitative Analysis of the Perceptions of People Suffering from OA. Towards the Development of a Specific Pain OA-Related Questionnaire, the Osteoarthritis Symptom Inventory Scale (OASIS). PLoS ONE, 2013, 8, e79988.	2.5	42
126	c-Fos immunoreactivity induced by intraperitoneal LPS administration is reduced in the brain of mice lacking the microsomal prostaglandin E synthase-1 (mPGES-1). Brain, Behavior, and Immunity, 2007, 21, 1109-1121.	4.1	41

Francis Berenbaum

#	Article	IF	CITATIONS
127	Mechanical stress and prostaglandin E2 synthesis in cartilage. Biorheology, 2008, 45, 301-320.	0.4	41
128	Predictive Factors of Eczema-Like Eruptions among Patients without Cutaneous Psoriasis Receiving Infliximab: A Cohort Study of 92 Patients. Dermatology, 2009, 219, 263-267.	2.1	41
129	Intra-articular injections in thumb osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. Joint Bone Spine, 2015, 82, 315-319.	1.6	41
130	The nuclear factor-erythroid 2-related factor/heme oxygenase-1 axis is critical for the inflammatory features of type 2 diabetes–associated osteoarthritis. Journal of Biological Chemistry, 2017, 292, 14505-14515.	3.4	41
131	VIOXX and cardiovascular events: a class effect?. Joint Bone Spine, 2005, 72, 1-3.	1.6	40
132	Cohort profile: The Applied Public-Private Research enabling OsteoArthritis Clinical Headway (IMI-APPROACH) study: a 2-year, European, cohort study to describe, validate and predict phenotypes of osteoarthritis using clinical, imaging and biochemical markers. BMJ Open, 2020, 10, e035101.	1.9	40
133	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatology, The, 2021, 3, e707-e714.	3.9	40
134	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology, 2022, 61, SI143-SI150.	1.9	40
135	Fears and Beliefs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Study. PLoS ONE, 2014, 9, e114350.	2.5	39
136	Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic diseases in daily practice in France. Joint Bone Spine, 2016, 83, 501-509.	1.6	39
137	Obesity and osteoarthritis: what are the links?. Joint Bone Spine, 2008, 75, 667-668.	1.6	38
138	Five-year Favorable Outcome of Patients with Early Rheumatoid Arthritis in the 2000s: Data from the ESPOIR Cohort. Journal of Rheumatology, 2013, 40, 1650-1657.	2.0	38
139	Increased prevalence and severity of radiographic hand osteoarthritis in patients with HIV-1 infection associated with metabolic syndrome: data from the cross-sectional METAFIB-OA study. Annals of the Rheumatic Diseases, 2016, 75, 2101-2107.	0.9	38
140	Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. Clinical Rheumatology, 2016, 35, 857-861.	2.2	38
141	Effect of age at rheumatoid arthritis onset on clinical, radiographic, and functional outcomes: The ESPOIR cohort. Joint Bone Spine, 2016, 83, 511-515.	1.6	38
142	Hypertension meets osteoarthritis — revisiting the vascular aetiology hypothesis. Nature Reviews Rheumatology, 2021, 17, 533-549.	8.0	38
143	Involvement of the notch pathway in the regulation of matrix metalloproteinase 13 and the dedifferentiation of articular chondrocytes in murine cartilage. Arthritis and Rheumatism, 2009, 60, 428-439.	6.7	37
144	AA amyloidosis treated with tocilizumab: case series and updated literature review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 84-92.	3.0	37

#	Article	IF	CITATIONS
145	HC-gp39 contributes to chondrocyte differentiation by inducing SOX9 and type II collagen expressions. Osteoarthritis and Cartilage, 2007, 15, 138-146.	1.3	36
146	<i>Festina lente</i> : hydroxychloroquine, COVID-19 and the role of the rheumatologist. Annals of the Rheumatic Diseases, 2020, 79, 734-736.	0.9	35
147	Regulation of the acetylcholine/α7nAChR anti-inflammatory pathway in COVID-19 patients. Scientific Reports, 2021, 11, 11886.	3.3	35
148	Danger signals and inflammaging in osteoarthritis. Clinical and Experimental Rheumatology, 2019, 37 Suppl 120, 48-56.	0.8	35
149	New Target Genes for NOV/CCN3 in Chondrocytes: TGF-β2 and Type X Collagen. Journal of Bone and Mineral Research, 2005, 20, 2213-2223.	2.8	34
150	Assessment and determinants of aesthetic discomfort in hand osteoarthritis. Annals of the Rheumatic Diseases, 2012, 71, 45-49.	0.9	34
151	Deep phenotyping of osteoarthritis: a step forward. Annals of the Rheumatic Diseases, 2019, 78, 3-5.	0.9	34
152	Efficacy of Lumiracoxib in Osteoarthritis: A Review of Nine Studies. Journal of International Medical Research, 2005, 33, 21-41.	1.0	32
153	Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor. Expert Opinion on Investigational Drugs, 2005, 14, 521-533.	4.1	31
154	Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohort. Rheumatology, 2010, 49, 147-155.	1.9	31
155	Inhibition of Matrix Metalloproteinase-3 and -13 Synthesis Induced by IL-1β in Chondrocytes from Mice Lacking Microsomal Prostaglandin E Synthase-1. Journal of Immunology, 2010, 185, 6244-6252.	0.8	31
156	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty. Drugs and Aging, 2015, 32, 525-535.	2.7	31
157	Development of a core capability framework for qualified health professionals to optimise care for people with osteoarthritis: an OARSI initiative. Osteoarthritis and Cartilage, 2020, 28, 154-166.	1.3	31
158	Needs, Experiences, and Views of People With Rheumatic and Musculoskeletal Diseases on Self-Management Mobile Health Apps: Mixed Methods Study. JMIR MHealth and UHealth, 2020, 8, e14351.	3.7	31
159	Role of the autonomic nervous system in osteoarthritis. Best Practice and Research in Clinical Rheumatology, 2017, 31, 661-675.	3.3	30
160	Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations. RMD Open, 2019, 5, e001004.	3.8	30
161	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. Lancet Rheumatology, The, 2022, 4, e237-e240.	3.9	30
162	Insulin-like growth factors counteract the effect of interleukin 1β on type II phospholipase A2 expression and arachidonic acid release by rabbit articular chondrocytes. FEBS Letters, 1994, 340, 51-55.	2.8	29

#	Article	IF	CITATIONS
163	A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 2014, 44, 271-282.	3.4	29
164	Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus. Molecules, 2021, 26, 2593.	3.8	29
165	Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. Arthritis Research and Therapy, 2014, 16, 481.	3.5	27
166	Body mass index and response to abatacept in rheumatoid arthritis. European Journal of Clinical Investigation, 2016, 46, 1048-1052.	3.4	26
167	Impairment of glyoxalase-1, an advanced glycation end-product detoxifying enzyme, induced by inflammation in age-related osteoarthritis. Arthritis Research and Therapy, 2019, 21, 18.	3.5	26
168	Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort. PLoS ONE, 2015, 10, e0134974.	2.5	26
169	Potential Role of Hyaluronic Acid on Bone in Osteoarthritis: Matrix Metalloproteinases, Aggrecanases, and RANKL Expression are Partially Prevented by Hyaluronic Acid in Interleukin 1-stimulated Osteoblasts. Journal of Rheumatology, 2014, 41, 945-954.	2.0	25
170	Does platelet-rich plasma deserve a role in the treatment of tendinopathy?. Joint Bone Spine, 2015, 82, 230-234.	1.6	25
171	Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey. Clinical Rheumatology, 2017, 36, 485-497.	2.2	25
172	Bone loss in primary biliary cirrhosis: absence of association with severity of liver disease. Joint Bone Spine, 2002, 69, 195-200.	1.6	24
173	The social (media) side to rheumatology. Nature Reviews Rheumatology, 2014, 10, 314-318.	8.0	24
174	Inflammation in osteoarthritis: changing views. Osteoarthritis and Cartilage, 2015, 23, 1823-1824.	1.3	24
175	Coronary heart disease is associated with a worse clinical outcome of hand osteoarthritis: a cross-sectional and longitudinal study. RMD Open, 2017, 3, e000344.	3.8	24
176	Reduction of the Serum Levels of a Specific Biomarker of Cartilage Degradation (Coll2-1) by Hyaluronic Acid (KARTILAGE® CROSS) Compared to Placebo in Painful Knee Osteoarthritis Patients: the EPIKART Study, a Pilot Prospective Comparative Randomized Double Blind Trial. BMC Musculoskeletal Disorders, 2017, 18, 222.	1.9	24
177	Lumiracoxib in the management of osteoarthritis and acute pain. Expert Opinion on Pharmacotherapy, 2007, 8, 1551-1564.	1.8	23
178	The pro-inflammatory cytokine s14-3-3ε is a ligand of CD13/Aminopeptidase N in cartilage. Journal of Cell Science, 2015, 128, 3250-62.	2.0	23
179	The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical. Arthritis Research and Therapy, 2017, 19, 115.	3.5	23
180	TGFβi is involved in the chondrogenic differentiation of mesenchymal stem cells and is dysregulated in osteoarthritis. Osteoarthritis and Cartilage, 2019, 27, 493-503.	1.3	23

#	Article	IF	CITATIONS
181	The DIGICOD cohort: A hospital-based observational prospective cohort of patients with hand osteoarthritis–Âmethodology and baseline characteristics of the population. Joint Bone Spine, 2021, 88, 105171.	1.6	23
182	Use of machine learning in osteoarthritis research: a systematic literature review. RMD Open, 2022, 8, e001998.	3.8	23
183	Reliability, sensitivity to change and feasibility of three radiographic scoring methods for hand osteoarthritis. Annals of the Rheumatic Diseases, 2011, 70, 1465-1467.	0.9	22
184	Reporting of patient-perceived impact of rheumatoid arthritis and axial spondyloarthritis over 10 years: a systematic literature review. Rheumatology, 2014, 53, 1274-1281.	1.9	22
185	COX-3: Fact or fancy?. Joint Bone Spine, 2004, 71, 451-453.	1.6	21
186	Bone imaging findings in genetic and acquired lipodystrophic syndromes: an imaging study of 24 cases. Skeletal Radiology, 2016, 45, 1495-1506.	2.0	21
187	Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study. Leukemia and Lymphoma, 2018, 59, 1399-1405.	1.3	21
188	The Role of the Nonâ€neuronal Cholinergic System in Inflammation and Degradation Processes in Osteoarthritis. Arthritis and Rheumatology, 2020, 72, 2072-2082.	5.6	21
189	Role of adipose tissues in osteoarthritis. Current Opinion in Rheumatology, 2021, 33, 84-93.	4.3	21
190	Targeted therapies in osteoarthritis: a systematic review of the trials on www.clinicaltrials.gov. Best Practice and Research in Clinical Rheumatology, 2010, 24, 107-119.	3.3	20
191	Use of autologous growth factors in aging tendon and chronic tendinopathy. Frontiers in Bioscience - Elite, 2013, E5, 911-921.	1.8	20
192	Protective role of frizzled-related protein B on matrix metalloproteinase induction in mouse chondrocytes. Arthritis Research and Therapy, 2014, 16, R137.	3.5	20
193	The opioid epidemic: helping rheumatologists prevent a crisis. RMD Open, 2019, 5, e001029.	3.8	20
194	Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020. Joint Bone Spine, 2020, 87, 431-437.	1.6	20
195	Vagus nerve stimulation in musculoskeletal diseases. Joint Bone Spine, 2021, 88, 105149.	1.6	20
196	Efficacy of intra-articular corticosteroid injections in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. Joint Bone Spine, 2021, 88, 105198.	1.6	20
197	Potentiation of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis. Joint Bone Spine, 2007, 74, 446-452.	1.6	18
198	Association Between Vitamin D Deficiency and Disease Activity, Disability, and Radiographic Progression in Early Rheumatoid Arthritis: The ESPOIR Cohort. Journal of Rheumatology, 2020, 47, 1624-1628.	2.0	18

#	Article	IF	CITATIONS
199	B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2021-220549.	0.9	18
200	Mechanical stress and prostaglandin E2 synthesis in cartilage. Biorheology, 2008, 45, 301-20.	0.4	18
201	Crusted Norwegian scabies, an opportunistic infection, with tocilizumab in rheumatoid arthritis. Joint Bone Spine, 2011, 78, 402-404.	1.6	17
202	Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts. RMD Open, 2015, 1, e000128.	3.8	17
203	Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol. BMJ Open, 2018, 8, e021037.	1.9	17
204	Increase In Il-31 Serum Levels Is Associated With Reduced Structural Damage In Early Axial Spondyloarthritis. Scientific Reports, 2018, 8, 7731.	3.3	17
205	Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis. RMD Open, 2019, 5, e000897.	3.8	17
206	Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo. Annals of the Rheumatic Diseases, 2021, 80, 475-486.	0.9	17
207	Adipokines in Arthritis: New Kids on the Block. Current Rheumatology Reviews, 2009, 5, 226-232.	0.8	17
208	Potential Classification Criteria for Rheumatoid Arthritis After Two Years: Results From a French Multicenter Cohort. Arthritis Care and Research, 2013, 65, 1227-1234.	3.4	16
209	Translation of clinical problems in osteoarthritis into pathophysiological research goals. RMD Open, 2016, 2, e000224.	3.8	16
210	Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire. Annals of the Rheumatic Diseases, 2018, 77, 258-263.	0.9	16
211	Pain in women with knee and/or hip osteoarthritis is related to systemic inflammation and to adipose tissue dysfunction: Cross-sectional results of the KHOALA cohort. Seminars in Arthritis and Rheumatism, 2021, 51, 129-136.	3.4	16
212	The quest for the Holy Grail: a disease-modifying osteoarthritis drug. Arthritis Research and Therapy, 2007, 9, 111.	3.5	15
213	Response to Letter to the Editor entitled "Comments on â€~OARSI guidelines for the non-surgical management of knee osteoarthritis'― Osteoarthritis and Cartilage, 2014, 22, 890-891.	1.3	15
214	Early non-response to certolizumab pegol in rheumatoid arthritis predicts treatment failure at one year. Data from a randomised phase III clinical trial. Joint Bone Spine, 2018, 85, 59-64.	1.6	15
215	Clearing method for 3-dimensional immunofluorescence of osteoarthritic subchondral human bone reveals peripheral cholinergic nerves. Scientific Reports, 2020, 10, 8852.	3.3	15
216	Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews. RMD Open, 2021, 7, e001658.	3.8	15

#	Article	IF	CITATIONS
217	Effect of Transcutaneous Vagus Nerve Stimulation in Erosive Hand Osteoarthritis: Results from a Pilot Trial. Journal of Clinical Medicine, 2022, 11, 1087.	2.4	15
218	Proteomics: addressing the challenges of osteoarthritis. Drug Discovery Today, 2009, 14, 661-667.	6.4	14
219	Evolution of pain at 3 months by oral resveratrol in knee osteoarthritis (ARTHROL): protocol for a multicentre randomised double-blind placebo-controlled trial. BMJ Open, 2017, 7, e017652.	1.9	14
220	Development of classification criteria for hand osteoarthritis: comparative analyses of persons with and without hand osteoarthritis. RMD Open, 2020, 6, e001265.	3.8	14
221	Tackling osteoarthritis during COVID-19 pandemic. Annals of the Rheumatic Diseases, 2021, 80, 151-153.	0.9	14
222	Coxibs and NSAIDs – Is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007. Osteoarthritis and Cartilage, 2007, 15, 849-856.	1.3	13
223	Time for new outcome measures in hand osteoarthritis?. Nature Reviews Rheumatology, 2009, 5, 136-138.	8.0	13
224	Is sarcoma a complication of arterial femoro-popliteal bypass?. Joint Bone Spine, 2010, 77, 358-360.	1.6	13
225	Introduction to OARSI FDA initiative OAC special edition. Osteoarthritis and Cartilage, 2011, 19, 475-477.	1.3	13
226	Serum hepcidin level is not an independent surrogate biomarker of disease activity or of radiographic progression in rheumatoid arthritis: results from the ESPOIR cohort. Annals of the Rheumatic Diseases, 2013, 72, 312-314.	0.9	13
227	Development and application of a questionnaire to assess patient beliefs in rheumatoid arthritis and axial spondyloarthritis. Clinical Rheumatology, 2018, 37, 2649-2657.	2.2	13
228	Anatomopathologie et pathogénie de l'arthrose. Revue Du Rhumatisme (Edition Francaise), 2000, 67, 119-125.	0.0	12
229	Challenges and Advances in Targeting Remission in Axial Spondyloarthritis. Journal of Rheumatology, 2018, 45, 153-157.	2.0	12
230	Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort. Rheumatology, 2021, 60, 5073-5079.	1.9	12
231	Gremlin-1 and BMP-4 Overexpressed in Osteoarthritis Drive an Osteochondral-Remodeling Program in Osteoblasts and Hypertrophic Chondrocytes. International Journal of Molecular Sciences, 2022, 23, 2084.	4.1	12
232	Poor efficacy of TNF inhibitors in non-radiographic axial spondyloarthritis in the absence of objective signs: A bicentric retrospective study. Joint Bone Spine, 2018, 85, 461-468.	1.6	11
233	Group B Streptococcal Vertebral Osteomyelitis with Bacteraemia in an Adult with no Debilitating Condition. Scandinavian Journal of Infectious Diseases, 1999, 31, 316-317.	1.5	10
234	Report from the Hand Osteoarthritis Working Group at OMERACT 2018: Update on Core Instrument Set Development. Journal of Rheumatology, 2019, 46, 1183-1187.	2.0	10

#	Article	IF	CITATIONS
235	Targeting nerve growth factor to relieve pain from osteoarthritis: What can we expect?. Joint Bone Spine, 2019, 86, 127-128.	1.6	10
236	Osteoarthritis and gut microbiome. Joint Bone Spine, 2021, 88, 105203.	1.6	10
237	Neuropathic pain in the IMI-APPROACH knee osteoarthritis cohort: prevalence and phenotyping. RMD Open, 2021, 7, e002025.	3.8	10
238	Does broccoli protect from osteoarthritis?. Joint Bone Spine, 2014, 81, 284-286.	1.6	9
239	Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in France. Journal of Medical Economics, 2016, 19, 812-821.	2.1	9
240	Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?. European Journal of Pain, 2021, 25, 1525-1539.	2.8	9
241	Work Productivity Loss in Early Arthritis During the First 3 Years of Disease: A Study From a French National Multicenter Cohort. Arthritis Care and Research, 2014, 66, 1310-1318.	3.4	8
242	Overview of osteo-articular involvement in systemic sclerosis: Specific risk factors, clinico-sonographic evaluation, and comparison with healthy women from the French OFELY cohort. Best Practice and Research in Clinical Rheumatology, 2018, 32, 591-604.	3.3	8
243	Metabolic Syndrome and Osteoarthritis Distribution in the Hand Joints: A Propensity Score Matching Analysis From the Osteoarthritis Initiative. Journal of Rheumatology, 2021, 48, 1608-1615.	2.0	8
244	WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee. Journal of Rheumatology, 2022, 49, 615-621.	2.0	8
245	The association of the lipid profile with knee and hand osteoarthritis severity: the IMI-APPROACH cohort. Osteoarthritis and Cartilage, 2022, 30, 1062-1069.	1.3	8
246	Chronic use of non-steroidal anti-inflammatory drugs does not alter colonic mucosa of patients without diarrhoea. Alimentary Pharmacology and Therapeutics, 2001, 15, 1301-1306.	3.7	7
247	Preface. Best Practice and Research in Clinical Rheumatology, 2010, 24, 1-2.	3.3	7
248	Editorial: Osteoarthritis: When Chondrocytes Don't Wake Up on Time. Arthritis and Rheumatism, 2013, 65, 2233-2235.	6.7	7
249	French law: what about a reasoned reimbursement of serum vitamin D assays?. Psychologie & Neuropsychiatrie Du Vieillissement, 2016, 14, 377-382.	0.2	7
250	Baseline clinical characteristics of predicted structural and pain progressors in the IMI-APPROACH knee OA cohort. RMD Open, 2021, 7, e001759.	3.8	7
251	â€~Twitterland': a brave new world?. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212273.	0.9	7
252	The impact of COVID-19 on rheumatology training—results from the COVID-19 Global Rheumatology Alliance trainee survey. Rheumatology Advances in Practice, 2022, 6, rkac001.	0.7	7

#	Article	IF	CITATIONS
253	Pollutants: a candidate as a new risk factor for osteoarthritis—results from a systematic literature review. RMD Open, 2022, 8, e001983.	3.8	7
254	Selective cyclooxygenase-2 inhibitors: hope and facts. Joint Bone Spine, 2000, 67, 499-501.	1.6	6
255	Coxibs and NSAIDs – clearing the air. Osteoarthritis and Cartilage, 2005, 13, 545-547.	1.3	6
256	Fibroblastic rheumatism: Immunosuppressive therapy is not always required. Joint Bone Spine, 2014, 81, 178-179.	1.6	6
257	Core outcome measurement instrument selection for physical function in hand osteoarthritis using the OMERACT Filter 2.1 process. Seminars in Arthritis and Rheumatism, 2021, 51, 1311-1319.	3.4	6
258	Intra-articular therapies: patient preferences and professional practices in European countries. Rheumatology International, 2022, 42, 869-878.	3.0	6
259	Statin use and MRI subchondral bone marrow lesion worsening in generalized osteoarthritis: longitudinal analysis from Osteoarthritis Initiative data. European Radiology, 2022, 32, 3944-3953.	4.5	6
260	NSAIDs and aspirin: friends or foes?. Joint Bone Spine, 2003, 70, 89-90.	1.6	5
261	Novel Approach to Estimate Osteoarthritis Progression: Use of the Reliable Change Index in the Evaluation of Joint Space Loss. Arthritis Care and Research, 2019, 71, 300-307.	3.4	5
262	Serum calprotectin is increased in early axial spondyloarthritis with sacroiliitis and objective signs of inflammation: Results from the DESIR cohort. Joint Bone Spine, 2021, 88, 105068.	1.6	5
263	General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, <scp>Placeboâ€Controlled</scp> Trials. Arthritis Care and Research, 2022, 74, 918-928.	3.4	5
264	What evidence is needed to demonstrate the beneficial effects of exercise for osteoarthritis?. Annals of the Rheumatic Diseases, 2022, 81, 451-453.	0.9	5
265	Development of radiographic classification criteria for hand osteoarthritis: a methodological report (Phase 2). RMD Open, 2022, 8, e002024.	3.8	5
266	Alpha-7 Nicotinic Receptor Dampens Murine Osteoblastic Response to Inflammation and Age-Related Osteoarthritis. Frontiers in Immunology, 2022, 13, 842538.	4.8	5
267	Time to Total Knee Arthroplasty after Intra-Articular Hyaluronic Acid or Platelet-Rich Plasma Injections: A Systematic Literature Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 3985.	2.4	5
268	Design of a chimeric promoter induced by pro-inflammatory mediators in articular chondrocytes. FEBS Letters, 2002, 518, 67-71.	2.8	4
269	Cardiometabolic risk factors in primary centred and rotator cuff-related shoulder osteoarthritis: a comparative study. RMD Open, 2017, 3, e000429.	3.8	4
270	Diabetes at the time of rheumatoid arthritis diagnosis is an independent predictor of pejorative outcomes: Data from the early arthritis ESPOIR cohort. Joint Bone Spine, 2018, 85, 773-775.	1.6	4

#	Article	IF	CITATIONS
271	Contribution of adipocyte precursors in the phenotypic specificity of intra-articular adipose tissues in knee osteoarthritis patients. Arthritis Research and Therapy, 2019, 21, 252.	3.5	4
272	Recommandations de la Société française de rhumatologie sur la prise en charge pharmacologique de la gonarthrose. Revue Du Rhumatisme (Edition Francaise), 2020, 87, 439-446.	0.0	4
273	The differentiation of prehypertrophic into hypertrophic chondrocytes drives an OA-remodeling program and IL-34 expression. Osteoarthritis and Cartilage, 2021, 29, 257-268.	1.3	4
274	Vitamin K and osteoarthritis: is there a link?. Annals of the Rheumatic Diseases, 2021, 80, 547-549.	0.9	4
275	Impact of Collagen Crosslinking on Dislocated Human Shoulder Capsules—Effect on Structural and Mechanical Properties. International Journal of Molecular Sciences, 2022, 23, 2297.	4.1	4
276	Transcutaneous vagus nerve stimulation in erosive hand osteoarthritis: protocol for the randomised, double-blind, sham-controlled ESTIVAL trial. BMJ Open, 2022, 12, e056169.	1.9	4
277	OUP accepted manuscript. Rheumatology, 2022, , .	1.9	4
278	An intra-articular, extended release formulation of triamcinolone (FX006) affords clinically relevant improvements in pain and function of knee osteoarthritis: post-hoc pooled analyses of 3 randomized controlled trials. Osteoarthritis and Cartilage, 2017, 25, S432-S433.	1.3	3
279	e-Health, social media, and rheumatology: Can they get along?. Joint Bone Spine, 2018, 85, 265-266.	1.6	3
280	Is hip osteoarthritis preventable?. Joint Bone Spine, 2020, 87, 371-375.	1.6	3
281	Metacarpophalangeal Joint Impairment in Hand Osteoarthritis and Its Association With Mechanical Factors: Results From the Digital Cohort Osteoarthritis Design Hand Osteoarthritis Cohort. Arthritis Care and Research, 2022, 74, 1696-1703.	3.4	3
282	Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis. Rheumatology and Therapy, 2021, 8, 1759-1774.	2.3	3
283	Blood ferritin and isoferritins measurements may be helpful in acute respiratory distress syndrome patients. Intensive Care Medicine, 2002, 28, 998-998.	8.2	2
284	Cartilage in the context of hyperglycemia and diabetes: Further pathophysiological clues for diabetes-related osteoarthritis. Osteoarthritis and Cartilage, 2015, 23, A293.	1.3	2
285	Sustained and profound analgesic benefits in people with osteoarthritis of the knee using FX006, an intra-articular extended-release formulation of triamcinolone acetonide: Results from a double-blind, randomized, parallel-group, dose-ranging study. Osteoarthritis and Cartilage, 2016, 24, S49-S50.	1.3	2
286	Recommendations of the French society of rheumatology for the pharmacological management of knee osteoarthritis. Osteoarthritis and Cartilage, 2019, 27, S507-S508.	1.3	2
287	Activating the cholinergic system a novel opportunity for treating osteoarthritis. Osteoarthritis and Cartilage, 2019, 27, S38.	1.3	2
288	Calprotectin alone is not sufficient to predict response to methotrexate in early ACR/EULAR 2010 rheumatoid arthritis: Analysis of the ESPOIR cohort. Joint Bone Spine, 2020, 87, 99-100.	1.6	2

#	Article	IF	CITATIONS
289	Critical role of C/EBPdelta and C/EBPbeta factors in the stimulation of the cyclooxygenase-2 gene transcription by interleukin-1beta in articular chondrocytes. FEBS Journal, 2000, 267, 6798-6809.	0.2	2
290	Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo ontrolled trials. International Journal of Clinical Practice, 2021, 75, e14975.	1.7	2
291	Arthrose et obésitéÂ: modèles expérimentaux. Revue Du Rhumatisme (Edition Francaise), 2008, 75, 1215-1219.	0.0	1
292	Is radiographic knee osteoarthritis more severe when hand osteoarthritis is present and conversely? A cross-sectional study in 1371 knee osteoarthritis patients. Osteoarthritis and Cartilage, 2013, 21, S246.	1.3	1
293	Infrapatellar fat pad induces an inflammatory and catabolic phenotype on autologous fibroblast-like synoviocytes from severe knee oa patients. Osteoarthritis and Cartilage, 2014, 22, S448.	1.3	1
294	Response to â€~Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort' – authors' reply. Arthritis Research and Therapy, 2014, 16, 408.	3.5	1
295	Cardiometabolic disturbances and hand osteoarthritis: A cross-sectional and longitudinal study. Osteoarthritis and Cartilage, 2015, 23, A53.	1.3	1
296	TGFb-induced Protein is Dysregulated in Osteoarthritis. Osteoarthritis and Cartilage, 2017, 25, S325-S326.	1.3	1
297	Osteoarthritis: Research in motion. Best Practice and Research in Clinical Rheumatology, 2017, 31, 611-612.	3.3	1
298	Intersite comparison and test-retest reliability of cartilage thickness and compostional analysis in the approach study – a 2-year multicenter European exploratory study for phenotype characterizaton of knee osteoarthritis. Osteoarthritis and Cartilage, 2019, 27, S326-S327.	1.3	1
299	Osteoarthritis Research Society International (OARSI): Past, present and future. Osteoarthritis and Cartilage Open, 2021, 3, 100146.	2.0	1
300	Impact of carpal tunnel syndrome on symptoms and structural severity of hand osteoarthritis: results from the DIGICOD cohort. Clinical Rheumatology, 2022, 41, 947-950.	2.2	1
301	99mTc-NTP 15-5 is a companion radiotracer for assessing joint functional response to sprifermin (rhFGF-18) in a murine osteoarthritis model. Scientific Reports, 2022, 12, 8146.	3.3	1
302	Mise en évidence d'une réaction inflammatoire systémique par dosage de la protéine C-réactive plasmatique au cours de la lombosciatique par hernie discale. Revue Du Rhumatisme (Edition) Tj ETQq0 0 0 rgBT	/Overlock	1@Tf 50 217
303	Potentialisation deÂlaÂfluindione etÂdeÂlaÂwarfarine parÂlaÂdexaméthasone dansÂleÂmyélome multiple etÂl'amylose AL. Revue Du Rhumatisme (Edition Francaise), 2007, 74, 845-851.	0.0	0
304	Inflammation et pathologies articulaires. Revue Francophone Des Laboratoires, 2007, 2007, 37-42.	0.0	0
305	Utilisation deÂl'infliximab dansÂleÂtraitement duÂrhumatisme psoriasique auÂcours deÂl'infection parÂleÂvirus deÂl'immunodéficience humaine (VIH). Revue Du Rhumatisme (Edition Francaise), 2007, 74, 297-300.	0.0	0
306	Osteoblast: A cell under compression. Bio-Medical Materials and Engineering, 2008, 18, 221-224.	0.6	0

#	Article	IF	CITATIONS
307	Génétique des maladies du cartilage (arthrose, chondrodysplasies). Revue Du Rhumatisme Monographies, 2010, 77, 321-327.	0.0	0
308	433 IMPROVEMENT OF THE REPRODUCIBILITY OF THE RADIOGRAPHIC KELLGREN-LAWRENCE (KL) SCORING SYSTEM IN HAND OSTEOARTHRITIS (HOA) USING A NEW KL SCORING SYSTEM AID. Osteoarthritis and Cartilage, 2010, 18, S193-S194.	1.3	0
309	Le sarcome est-il une complication du pontage artériel fémoro-poplité�. Revue Du Rhumatisme (Edition) 1	[j ETQq1 ∶ 0.0	1 0.784314
310	Management of Osteoarthritis. , 2010, , 303-316.		0
311	Paper # 219: Cell Therapies Enhance Bone Tendon Healing in a Degenerative Model of Enthesis Lesion. Arthroscopy - Journal of Arthroscopic and Related Surgery, 2011, 27, e216-e217.	2.7	0
312	Gale croûteuse norvégienne, une infection opportuniste, survenant sous tocilizumab dans le traitement de la polyarthrite rhumatoÃ⁻de. Revue Du Rhumatisme (Edition Francaise), 2011, 78, 382-384.	0.0	0
313	Induction de la chimiokine IL-8/Kc par le cartilageÂ: rÃ1e potentiel dans l'arthrose. Revue Du Rhumatisme (Edition Francaise), 2012, 79, 412-417.	0.0	0
314	Secreted 14-3-3ε: discovery by proteomics of a novel biomarker and/or therapeutical target in osteoarthritis. Osteoarthritis and Cartilage, 2013, 21, S225-S226.	1.3	0
315	Clinical image: Spondylodiscitis due to a fistula between L5-S1 disc and colon. Joint Bone Spine, 2013, 80, 100-101.	1.6	0
316	Rhumatisme fibroblastiqueÂ: le traitement immunosuppresseur n'est pas toujours requis. Revue Du Rhumatisme (Edition Francaise), 2014, 81, 185-187.	0.0	0
317	What happens to Kellgren-Lawrence grade 1 joints in hand osteoarthritis (OA) after 2.6 years ? "OA or not OA that is the question ?â€+ Data from the SEKOIA trial. Osteoarthritis and Cartilage, 2014, 22, S270.	1.3	0
318	Quelle place pour les PRP (plasma riche en plaquettes) dans les tendinopathiesÂ?. Revue Du Rhumatisme (Edition Francaise), 2015, 82, 80-84.	0.0	0
319	Critical role of CD13/aminopeptidase N in bone/cartilage communication in osteoarthritis: Ability to bind 14-3-3E. Osteoarthritis and Cartilage, 2015, 23, A161.	1.3	0
320	Présentation clinique des patients souffrant de rachialgie inflammatoire chronique récente évocatrice de spondyloarthriteÂ: la cohorte Desir. Revue Du Rhumatisme (Edition Francaise), 2015, 82, 378-385.	0.0	0
321	High Levels Of Fears Of Patients With Rheumatoid Arthritis Or Axial Spondyloarthritis Are Associated With Gender, Disease Activity, Anxiety And Depression: A Cross-Sectional Study Of 672 Patients. Value in Health, 2016, 19, A473-A474.	0.3	0
322	Knee and hip intra-articular adipose tissues share a common phenotype in osteoarthritis. Osteoarthritis and Cartilage, 2016, 24, S339.	1.3	0
323	Response to: â€~Does the prevalence of radiographic hand osteoarthritis in patients with HIV-1 infection increase or not?' by Luo <i>et al</i> . Annals of the Rheumatic Diseases, 2016, 75, e52-e52.	0.9	0

 $04.03 \hat{a} \in ... Tg f\hat{l}^2 \text{-induced protein (tg f\hat{l}^2 i) is dysregulated in osteoarthritis., 2017, , .$

#	Article	IF	CITATIONS
325	Collecte et prise en charge de certaines comorbidités et facteurs de risque associés dans le cadre des rhumatismes inflammatoires chroniques dans la pratique quotidienne en France. Revue Du Rhumatisme (Edition Francaise), 2017, 84, 123-131.	0.0	0
326	Effet de l'âge d'apparition de la polyarthrite rhumatoÃ⁻de sur l'évolution clinique, radiographique o fonctionnelleÂ: la cohorte ESPOIR. Revue Du Rhumatisme (Edition Francaise), 2017, 84, 498-503.	et 0.0	0
327	Investigating the role of panx3 in mechanostimulation and pro-inflammatory responses in chondrocytes. Osteoarthritis and Cartilage, 2017, 25, S150-S151.	1.3	0
328	The French Patient's Association (Aflar: French League Against Rheumatism) has Generated The French National Alliance Against Osteoarthritis and the First General Convention of Osteoarthritis in France: A Campaign to Create a National Lobbying Tool to Improve the Management of Osteoarthritis. Osteoarthritis and Cartilage, 2017, 25, S221-S222.	1.3	0
329	08.26â€The prevalence of acpa is lower in rheumatoid arthritis patients with a higher age of onset but the composition of the acpa response appears identical. , 2017, , .		0
330	Prehypertrophic to hypertrophic differentiation of chondrocytes induces IL-34 expression, a new cytokine with potential osteochondral junction remodeling activity in osteoarthritis. Osteoarthritis and Cartilage, 2018, 26, S68-S69.	1.3	0
331	Implication of 14-3-3epsilon as a potential alarmin in bone/cartilage communication in osteoarthritis. Osteoarthritis and Cartilage, 2018, 26, S62.	1.3	0
332	SP0060â€Eular recommendations for the use of imaging in mechanical low back pain. , 2018, , .		0
333	La présence de diabète lors du diagnostic de la polyarthrite rhumatoÃ⁻de est un facteur indépendant prédictif de mauvais résultatsÂ: données de la cohorte ESPOIR sur les polyarthrites récentes. Revue Du Rhumatisme (Edition Francaise), 2019, 86, 534-536.	0.0	0
334	Arthrose et diabète : pourquoi ? Les données fondamentales. Medecine Des Maladies Metaboliques, 2019, 13, 320-323.	0.1	0
335	Gait kinematics for patients with early stage knee osteoarthritis in the approach project. Osteoarthritis and Cartilage, 2019, 27, S114-S115.	1.3	0
336	14-3-3E, a new alarmin candidate, elicits a catabolic and proinflammatory effect involving innate immunity through TLR signaling in osteoarthritis. Osteoarthritis and Cartilage, 2019, 27, S375-S376.	1.3	0
337	THU0642â€EULAR POINTS TO CONSIDER FOR THE DEVELOPMENT, EVALUATION AND IMPLEMENTATION OF MOBILE HEALTH APPLICATIONS FOR SELF-MANAGEMENT IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES. , 2019, , .		0
338	AB1350â€HOW TO REDUCE THE NOCEBO EFFECT IN RHEUMATOLOGY? A SYSTEMATIC REVIEW OF RISK FACTORSAND INTERVENTION STRATEGIES. , 2019, , .		0
339	FRI0100â€TOWARDS THE LOWEST EFFICACIOUS DOSE (TOLEDO): RESULTS OF A MULTICENTER NON-INFERIORITY RANDOMIZED OPEN-LABEL CONTROLLED TRIAL ASSESSING TOCILIZUMAB OR ABATACEPT INJECTION SPACING IN RHEUMATOID ARTHRITIS PATIENTS IN REMISSION. , 2019, , .		0
340	AB0104â€ARE POLLUTANTS A NEW RISK FACTOR FOR OSTEOARTHRITIS? RESULTS FROM A SYSTEMATIC LITERATURE REVIEW. , 2019, , .		0
341	SP0001â€WIN IN OA MANAGEMENT. , 2019, , .		0
342	LB0007â€SUBCUTANEOUS TANEZUMAB FOR OSTEOARTHRITIS PAIN: A 24-WEEK PHASE 3 STUDY WITH A		0

24-WEEK FOLLOW UP. , 2019, , .

#	Article	IF	CITATIONS
343	Response to: â€~Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis' by Singer <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e162-e162.	0.9	Ο
344	Response to: â€~Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera. Annals of the Rheumatic Diseases, 2022, 81, e66-e66.	0.9	0
345	How the COVID-19 pandemic has affected rheumatology research. Nature Reviews Rheumatology, 2022, 18, 128-132.	8.0	Ο
346	Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination. Arthritis Research and Therapy, 2022, 24, 72.	3.5	0